Nasus Pharma annual ebitda
2022
2023
2024
2025
Nasus Pharma EBITDA Growth & History (NSRX)
Nasus Pharma's calculated EBITDA was −$4.9M for fiscal 2025.
View full Nasus Pharma company overviewNasus Pharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$4.9M | −$3.8M | — |
| 2024 | 2024-12-31 | −$1.1M | $69,000 | — |
| 2023 | 2023-12-31 | −$1.1M | $987,000 | — |
| 2022 | 2022-12-31 | −$2.1M | — | — |
Nasus Pharma ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Nasus Pharma's ebitda decreased from −$2.1M to −$4.9M, a change of −$2.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nasus Pharma source filings ↗